Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.40 |
| ▸ | MME | P08473 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26765974 | 1.00 | NPC1 (0.44) | NPC1RAB9ACHRNB4CHRNA3LMNA | |
| SCHEMBL22810961 | 0.90 | POLB (0.49) | LMNAGAAKMT2AMMEACE | |
| SCHEMBL2734908 | 0.90 | POLB (0.49) | LMNAGAAKMT2AMMEACE | |
| SCHEMBL15313443 | 0.90 | POLB (0.49) | LMNAGAAKMT2AMMEACE | |
| SCHEMBL21699252 | 0.90 | POLB (0.49) | LMNAGAAKMT2AMMEACE | |
| SCHEMBL9892967 | 0.90 | POLB (0.49) | LMNAGAAKMT2AMMEACE | |
| SCHEMBL19647312 | 0.89 | GAA (0.54) | LMNAGAA | |
| SCHEMBL18912329 | 0.89 | GAA (0.54) | LMNAGAA | |
| SCHEMBL18683750 | 0.87 | NPC1 (0.41) | NPC1RAB9ALMNAGAAMEN1 | |
| SCHEMBL22476513 | 0.85 | GAA (0.42) | GAAACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020219770-A1 | ANTI-CD117 ANTIBODIES AND USES THEREOF | Magenta Therapeutics, Inc. (US) | 2020-10-29 | — | — | WO | disclosed |